Related Experiment Videos
Methotrexate pharmacokinetics and survival in osteosarcoma
Irene Aquerreta1, Azucena Aldaz, Joaquín Giráldez
1Department of Pharmacy, University Hospital of Navarra, Pamplona, Spain. iaquerreta@unav.es
Pediatric Blood & Cancer
|January 31, 2004
Summary
High-dose methotrexate (HDMTX) exposure is linked to better survival in pediatric osteosarcoma. Achieving an area under the curve (AUC) above 4,000 micromol/L hr is recommended for improved treatment response.
Area of Science:
- Pediatric Oncology
- Pharmacokinetics
- Medical Research
Background:
- Osteosarcoma is a common bone cancer in children.
- High-dose methotrexate (HDMTX) is a key chemotherapy agent used in osteosarcoma treatment.
- Understanding the relationship between HDMTX exposure and treatment outcomes is crucial for optimizing therapy.
Purpose of the Study:
- To investigate the association between high-dose methotrexate (HDMTX) exposure and tumor response in pediatric osteosarcoma patients.
- To determine the optimal methotrexate exposure levels for improved survival outcomes.
- To analyze the impact of methotrexate dose density on treatment efficacy.
Main Methods:
- Retrospective analysis of 44 pediatric osteosarcoma patients who received 479 courses of HDMTX.
- Median MTX dose of 5.92 g/m2 administered via 4-hr infusion.
- Exposure parameters included mean area under the concentration-time curve (AUC) and end-infusion concentration, estimated using non-parametric expectation maximization (NPEM).
- Tumor response assessed by disease-free survival (DFS), overall survival (OS), and histologic tumor response.
- Cox regression analysis was employed to evaluate the relationship between MTX exposure and survival.
Main Results:
- Patients with lower MTX exposure (AUC < 2,400 micromol/L hr) showed high DFS, potentially due to increased dose density.
- An increasing MTX AUC was correlated with improved DFS in patients with AUC > 2,400 micromol/L hr.
- A significant difference in DFS was observed between patients with mean AUC below and above 4,000 micromol/L hr (P=0.024).
- An AUC of 4,000 micromol/L hr was identified as a target minimum exposure level.
Conclusions:
- Methotrexate dose density appears to be a significant factor influencing osteosarcoma response.
- Achieving a mean MTX AUC exceeding 4,000 micromol/L hr is recommended to enhance treatment effectiveness in pediatric osteosarcoma.
- Further studies are warranted to confirm the role of dose density and optimize HDMTX dosing strategies.